Gisev Natasa, Bell J Simon, Chen Timothy F
From the *Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales; †Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; ‡School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; and §School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Adelaide, Australia.
J Clin Psychopharmacol. 2014 Jun;34(3):307-12. doi: 10.1097/JCP.0000000000000098.
Community treatment orders (CTOs) are a form of compulsory treatment of individuals with a mental illness in the community. The objectives of this study were to determine the demographic, clinical, and treatment plan factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with a CTO. This was a secondary analysis of all 377 individuals who were prescribed an antipsychotic, extracted from a retrospective study of 378 individuals issued with a CTO by the New South Wales Mental Health Review Tribunal in Australia in 2009. Deidentified information relating to individuals' treatment plans, demographic, and clinical details were systematically extracted. Of the 377 individuals, 121 (32%) were prescribed antipsychotic polypharmacy and 101 (27%) high-dose antipsychotics. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for factors associated with antipsychotic polypharmacy and high-dose antipsychotics were computed using binary logistic regression. There was a strong association between the use of antipsychotic polypharmacy and high-dose antipsychotics (P < 0.001). Only treatment plan factors were associated with antipsychotic polypharmacy and high-dose antipsychotics in adjusted models. Although first-generation long-acting injectable antipsychotics and clozapine were associated with antipsychotic polypharmacy (adjusted OR, 9.12; 95% CI, 4.21-19.74; adjusted OR, 7.97; 95% CI, 2.93-21.72), oral second-generation antipsychotics and risperidone long-acting injection were associated with high-dose antipsychotics (adjusted OR, 5.67; 95% CI, 2.89-11.12; adjusted OR, 8.14; 95% CI, 3.22-20.53). Therefore, the use of antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with CTOs is associated only with the drugs prescribed in their treatment plans and not their individual demographic and clinical characteristics.
社区治疗令(CTOs)是针对患有精神疾病的个人在社区中进行强制治疗的一种形式。本研究的目的是确定与接受社区治疗令的个人中抗精神病药物联合使用及高剂量抗精神病药物相关的人口统计学、临床和治疗计划因素。这是对所有377名服用抗精神病药物的个体进行的二次分析,数据提取自澳大利亚新南威尔士州心理健康复审法庭2009年对378名接受社区治疗令的个体进行的回顾性研究。系统提取了与个体治疗计划、人口统计学和临床细节相关的去识别信息。在这377名个体中,121名(32%)接受了抗精神病药物联合治疗,101名(27%)接受了高剂量抗精神病药物治疗。使用二元逻辑回归计算与抗精神病药物联合使用及高剂量抗精神病药物相关因素的未调整和调整后的优势比(OR)及95%置信区间(95%CI)。抗精神病药物联合使用与高剂量抗精神病药物之间存在强关联(P < 0.001)。在调整模型中,只有治疗计划因素与抗精神病药物联合使用及高剂量抗精神病药物相关。虽然第一代长效注射用抗精神病药物和氯氮平与抗精神病药物联合使用有关(调整后的OR,9.12;95%CI,4.21 - 19.74;调整后的OR,7.97;95%CI,2.93 - 21.72),但口服第二代抗精神病药物和利培酮长效注射剂与高剂量抗精神病药物有关(调整后的OR,5.67;95%CI,2.89 - 11.12;调整后的OR,8.14;95%CI,3.22 - 20.53)。因此,接受社区治疗令的个体中抗精神病药物联合使用及高剂量抗精神病药物的使用仅与他们治疗计划中所开的药物有关,而与他们的个人人口统计学和临床特征无关。